Zacks Research Issues Negative Outlook for Novavax Earnings

Novavax, Inc. (NASDAQ:NVAX) – Investment analysts at Zacks Research cut their Q3 2026 EPS estimates for shares of Novavax in a report issued on Friday, May 22nd. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings of $0.08 per share for the quarter, down from their previous estimate of $0.09. The consensus estimate for Novavax’s current full-year earnings is ($0.20) per share. Zacks Research also issued estimates for Novavax’s Q4 2027 earnings at $0.14 EPS.

Other equities research analysts have also recently issued reports about the stock. B. Riley Financial reaffirmed a “buy” rating on shares of Novavax in a research report on Thursday, April 9th. Jefferies Financial Group reissued a “buy” rating on shares of Novavax in a research report on Thursday, March 12th. TD Cowen boosted their price target on shares of Novavax from $8.00 to $9.00 and gave the stock a “hold” rating in a research report on Wednesday, May 6th. HC Wainwright boosted their price target on shares of Novavax from $11.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Finally, Weiss Ratings cut shares of Novavax from a “hold (c-)” rating to a “sell (d)” rating in a research report on Thursday, May 7th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat, Novavax presently has an average rating of “Hold” and an average price target of $12.13.

Novavax Stock Performance

NVAX opened at $9.21 on Monday. The stock has a market capitalization of $1.51 billion, a P/E ratio of -15.88 and a beta of 2.37. Novavax has a 12 month low of $6.13 and a 12 month high of $11.97. The firm’s fifty day simple moving average is $8.85 and its 200 day simple moving average is $8.27.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.19. The business had revenue of $118.90 million for the quarter, compared to analysts’ expectations of $79.81 million. Novavax had a negative net margin of 14.73% and a negative return on equity of 14.82%. The firm’s revenue was down 79.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.93 EPS.

Institutional Investors Weigh In On Novavax

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in Novavax by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 15,470,365 shares of the biopharmaceutical company’s stock worth $103,961,000 after buying an additional 275,802 shares in the last quarter. Shah Capital Management lifted its position in Novavax by 2.0% during the 1st quarter. Shah Capital Management now owns 14,845,097 shares of the biopharmaceutical company’s stock worth $120,839,000 after buying an additional 286,317 shares in the last quarter. State Street Corp increased its stake in shares of Novavax by 32.3% during the 4th quarter. State Street Corp now owns 9,523,646 shares of the biopharmaceutical company’s stock worth $63,999,000 after purchasing an additional 2,326,927 shares during the last quarter. UBS Group AG increased its stake in shares of Novavax by 40.3% during the 4th quarter. UBS Group AG now owns 4,894,284 shares of the biopharmaceutical company’s stock worth $32,890,000 after purchasing an additional 1,405,981 shares during the last quarter. Finally, Bank of America Corp DE increased its stake in shares of Novavax by 0.5% during the 3rd quarter. Bank of America Corp DE now owns 3,101,074 shares of the biopharmaceutical company’s stock worth $26,886,000 after purchasing an additional 15,685 shares during the last quarter. 53.04% of the stock is owned by institutional investors.

About Novavax

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.